Please login to the form below

Not currently logged in
Email:
Password:

Lilly invests in biotechnology

Eli Lilly & Company has announced a multi-million dollar investment to expand its existing biotechnology capabilities in the US

Eli Lilly & Company has announced a multi-million dollar investment to expand its existing biotechnology capabilities in the US.

The investment will support research and development of multi-specific therapeutics, in which two or more distinct mechanisms of action are engineered in one molecule with the goal of providing enhanced efficacy with an improved safety profile.

Lilly said it is hiring additional biochemists and biologists to work at its biotechnology facilities in Indianapolis and San Diego.

Dr Jan M Lundberg, Lilly's executive vice president of science and technology and president of Lilly Research Laboratories, said: "Our further investment in multi-specific therapeutics underscores Lilly's commitment to the field of biotechnology and its importance to providing improved outcomes for individual patients."

Lilly's protein engineering expertise has been built internally in its Indianapolis biotechnology research group and through the earlier acquisition of Applied Molecular Evolution (AME).

Lilly is also analysing its historic library of protein and antibody assets, a compilation of molecules from decades of research in Lilly Research Laboratories, AME and ImClone, to determine their potential to be engineered into multi-specific therapeutics.

29th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics